Debes Jose D, Roberts Rosebud O, Jacobson Debra J, Girman Cynthia J, Lieber Michael M, Tindall Donald J, Jacobsen Steven J
Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):255-9. doi: 10.1158/1055-9965.epi-03-0093.
Calcium channel blockers block calcium signal-mediated apoptosis. It is hypothesized that the use of these drugs may be associated with the development of cancer. This study investigated the association between daily use of calcium channel blockers and prostate cancer in a community-based cohort of men who participated in a longitudinal study of lower urinary tract symptoms. Study subjects were men ages 40 to 79 years by January 1, 1990, and were randomly selected from Olmsted County in Minnesota. At baseline, participants underwent an interview to determine all medications taken on a daily basis, including calcium channel blockers and to elicit a family history of prostate cancer. During follow-up, all men with a histological diagnosis of prostate cancer were identified through patient self-report and by a review of the complete medical record. Over 12,668 person years of follow-up, 15 (6.8%) of 220 calcium channel blocker users and 120 (10.5%) of 1142 nonusers developed prostate cancer (P = 0.09; odds ratio, 0.62; 95% confidence interval, 0.36-1.10). With adjustment for age and family history of prostate cancer, the risk (odds ratio, 95% confidence interval) of prostate cancer was 0.55 (0.31-0.97) in calcium channel blocker users compared with nonusers. In analyses stratified by family history of prostate cancer, the risk of prostate cancer was 0.45 (0.23-0.88) in men without a family history and 2.64 (0.82-8.47) in men with a family history of prostate cancer (P = 0.006). These findings suggest an association between prostate cancer and daily use of calcium channel blockers that varies by family history of prostate cancer.
钙通道阻滞剂可阻断钙信号介导的细胞凋亡。据推测，使用这些药物可能与癌症的发生有关。本研究在一个参与下尿路症状纵向研究的社区男性队列中，调查了每日使用钙通道阻滞剂与前列腺癌之间的关联。研究对象为截至1990年1月1日年龄在40至79岁之间的男性，他们是从明尼苏达州的奥尔姆斯特德县随机选取的。在基线时，参与者接受了一次访谈，以确定每日服用的所有药物，包括钙通道阻滞剂，并了解前列腺癌家族史。在随访期间，通过患者自我报告和查阅完整病历，确定了所有经组织学诊断为前列腺癌的男性。在超过12668人年的随访中，220名钙通道阻滞剂使用者中有15人（6.8%）患前列腺癌，1142名非使用者中有120人（10.5%）患前列腺癌（P = 0.09；比值比，0.62；95%置信区间，0.36 - 1.10）。在对年龄和前列腺癌家族史进行调整后，与非使用者相比，钙通道阻滞剂使用者患前列腺癌的风险（比值比，95%置信区间）为0.55（0.31 - 0.97）。在按前列腺癌家族史分层的分析中，无家族史男性患前列腺癌的风险为0.45（0.23 - 0.88），有前列腺癌家族史男性患前列腺癌的风险为2.64（0.82 - 8.47）（P = 0.006）。这些发现表明，前列腺癌与每日使用钙通道阻滞剂之间存在关联，且这种关联因前列腺癌家族史而异。
